-
The value of the traditional Chinese medicine sector in the capital market is highlighted by the policy of innovation and acceleration
Time of Update: 2022-02-23
Innovations emerge Several listed companies announced product price increases From the point of view of application and registration, according to the statistics published by the Center for Drug Evaluation of the State Food and Drug Administration, the number of new Chinese medicine drug applications and registrations accepted in 2021 will be 62, an increase of 129.
-
Yang Liang, Vice President of Luye Pharma Investment: The Group will usher in a critical turning point
Time of Update: 2022-02-23
In the past few years, the promotion of some international projects has helped us to better familiarize ourselves with and adapt to different international market environments, so that the operation of our international system has become more mature and efficient, and we have formed a relatively advantageous international R&D, registered clinical , supply chain and commercialization capabilities, which have laid a very solid foundation for the launch of new products in the future .
-
The first in the country!
Time of Update: 2022-02-23
Article source: Medical Cube InfoOn January 10, the official website of CDE showed that the clinical application of Sunshine Guojian's monoclonal antibody SSGJ-617 targeting PSGL-1, a subsidiary of 3SBio, was accepted by the State Food and Drug Administration .
-
Health and Health Commission issues management measures for medical representative visits
Time of Update: 2022-02-23
In the era of the savage growth of the pharmaceutical market, pharmaceutical representatives traveled through the net of interests generated by disorderly competition and became the most active and cu
-
FDA approves AbbVie's JAK inhibitor Rinvoq for atopic dermatitis
Time of Update: 2022-02-23
S. Food and Drug Administration announced today that it has approved an expanded indication for AbbVie’s Rinvoq (upadacitinib) for the treatment of moderate-to-severe atopic dermatitis in adults or children 12 years and older who have not responded to prior therapy and are The condition cannot be controlled by other treatments, or other treatments should not be used .
-
AbbVie submits new indications for JAK inhibitor Rinvoq in the US and Europe
Time of Update: 2022-02-23
Recently, the company announced that it has submitted new indication applications for Rinvoq to regulatory agencies in the United States and Europe for the treatment of radiologically negative axial spondyloarthritis (nr-axSpA), which is specifically indicated for: nr-axSpA patients with insufficient response to inflammatory drugs and objective signs of inflammation .
-
A province adds nearly 10,000 licensed pharmacists
Time of Update: 2022-02-23
For example, the Liaoning Provincial Food and Drug Administration issued in May last year the "Notice on Regulating the Differentiation and Use of Licensed Pharmacists in Drug Retail Enterprises (Draft for Comment)", which mentioned that in the township and rural areas where there is an obvious shortage of licensed pharmacists, the operation of prescription drugs .
-
Under the general trend of Chinese medicine innovation, the development of industrial modernization also needs to be accelerated
Time of Update: 2022-02-22
Under the general trend of Chinese medicine innovation, the development of industrial modernization also needs to be accelerated (Photo source: Pharmaceutical Network) On the whole, these policies have mentioned the need to promote the inheritance, innovation and development of traditional Chinese medicine .
-
The State Food and Drug Administration approved 211 devices: United Imaging, Mindray, Shengxiang...
Time of Update: 2022-02-22
Among them, there are 136 domestic third-class medical device products, 43 imported third-class medical device products, 29 imported second-class medical device products, and 3 Hong Kong, Macao and Taiwan medical device products .
-
With the help of policies, the traditional Chinese medicine industry will usher in further benefits
Time of Update: 2022-02-22
For example, the Zhejiang Provincial Medical Insurance Bureau recently issued a notice on the implementation of the "Implementation Opinions on Supporting the Inheritance, Innovation and Development of Traditional Chinese Medicine" .
-
7 functional products will be discontinued immediately, and "health products pit old people" will be sentenced!
Time of Update: 2022-02-22
01 The market is reshuffled, and production and sales are not allowed if it is not included in the catalogue According to the content released by the function catalogue, the three health functions of promoting lactation, improving growth and development, and improving skin oil that are inconsistent with the existing health functions have been cancelled, and the former Ministry of Health has no longer accepted the approval of tumor suppression, auxiliary tumor suppression, and anti-mutation.
-
The newly revised "Class I Medical Device Product Catalog" was announced
Time of Update: 2022-02-22
In response to the problems of cold compresses, cold compress gel products with high class and low preparation, and non- medical devices being filed in accordance with the first class medical device, the newly revised "Class I Catalog" has revised the "09-02-03 Physical Cooling Equipment" in the 2017 version of the catalog.
-
Parecoxib Sodium for Injection by Conba passed the consistency evaluation of generic drugs
Time of Update: 2022-02-22
As of the disclosure date of this announcement, the manufacturers of parecoxib sodium for injection that have passed the consistency evaluation of the State Food and Drug Administration include Jinhua Kangenbei and other 27 companies (including those approved under the newly registered category 4 generic drugs are deemed to have passed the consistency evaluation) evaluation species) .
-
The Health and Health Commission has notified clinics and clinics that more than 500 kinds of drugs can be used
Time of Update: 2022-02-22
02 Variation 2: Rearrange and combine into twenty-two categories In addition to the increase in the total number, the drugs in the "Catalog" have been re-arranged and combined .
11 new diabetes drugs are added 03Change 3.
-
AstraZeneca/Daiichi Sankyo's new ADC indication has been granted priority review by the FDA
Time of Update: 2022-02-22
In this trial, Enhertu demonstrated a 72% reduction in the risk of disease progression or death in patients with HER2-positive unresectable and/or metastatic breast cancer previously treated with trastuzumab and a taxane compared with the active comparator (hazard ratio [HR]=0.
-
Haisco's application for clinical trial of HSK36273 for injection has been accepted
Time of Update: 2022-02-22
On January 17, Hisco announced that it had recently received the "Notice of Acceptance" issued by the State Drug Administration, and that HSK36273 for injection was approved for clinical trials .
Therefore, in many surgeries, systemic anticoagulation of patients is required to prevent perioperative thrombosis .
-
Xinhua Pharmaceutical's pioglitazone hydrochloride passed the consistency evaluation
Time of Update: 2022-02-22
("Xinda Pharmaceutical") received the "Approval Notice for Supplementary Drug Application" for pioglitazone hydrochloride capsules approved and issued by the State Food and Drug Administration.
Xinda Pharmaceutical is the first company in China to pass the consistency evaluation of pioglitazone hydrochloride capsules .
-
China's pharmaceutical equipment industry has ushered in a period of opportunity and will accelerate its development in three directions
Time of Update: 2022-02-22
On the whole, under the background of the continuous expansion of the market scale, the stricter industry supervision and the intensified competition, the pharmaceutical equipment enterprises are currently adapting to the market demand, accelerating technological innovation, expanding cooperation with foreign countries, and at a higher level, more Improve the manufacturing level and production capacity of China's pharmaceutical equipment on a large scale .
-
Shanghai biopharmaceutical industry has made good news!
Time of Update: 2022-02-22
Shanghai's biopharmaceutical industry can be described as a series of good news . On January 6, five new cities in Shanghai, Jiading, Songjiang, Qingpu, Fengxian and Nanhui, entered a new stage, and
-
Mutual complaints, real-name reports... 10 drugs were processed!
Time of Update: 2022-02-22
Second, for drugs of other companies under the same generic name that are not linked to the provincial procurement platform , the comparable price of the same generic name and the same medical insurance dosage form of the lowest unit is 1.